NCT03012581View on ClinicalTrials.gov

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types

PHASE2CompletedINTERVENTIONAL

Enrollment

269

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

December 22, 2022

Study Completion Date

November 11, 2023

Conditions

Carcinoma, Renal CellHead and Neck NeoplasmSkin NeoplasmsMicrosatellite InstabilityPenile NeoplasmsCancer With POLE Exonucleasic Domain Mutation

Interventions

DRUG

Nivolumab

Treatment

Trial Locations (1)

94805

Gustave Roussy Cancer Campus, Villejuif

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

Ligue contre le cancer, France

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

UNICANCER

OTHER